Optimizing First-Line Therapeutics in Non-Small Cell Lung Cancer: Insights from Joint Modeling and Large-Scale Data Analysis

Benjamin K. Schneider, Sebastien Benzekry, Jonathan P. Mochel

Non-small cell lung cancer (NSCLC) is often intrinsically resistant to several first- and second-line therapeutics and can rapidly acquire further resistance after a patient begins…